GlaxoSmithKline reported climbing sales but lower profits in the third quarter of 2015, as it continued its shift to a higher-volume, lower-margin business following its $20 billion asset swap deal with Novartis.
from WSJ.com: US Business http://ift.tt/1GIUsCp
via IFTTT
No comments:
Post a Comment